Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR T Cells and HSCs in Recurrent Ovarian Cancer
NCT03691376Phase 1Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2019
- Primary completion
- Jan 2021
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous NY-ESO-1-specific CD8-positive T lymphocytes and NY-ESO-1 CD4-TCR-transduced CD34+ hematopoietic stem cells in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Incidence of adverse events at 9 months and Maximum tolerated dose at 9 months. Started Mar 2019; status: terminated.
02
Drugs
autologous NY-ESO-1-specific CD8-positive T lymphocytesNY-ESO-1 CD4-TCR-transduced CD34+ hematopoietic stem cells
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03691376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691376.